Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study

  • End date
    Jul 19, 2022
  • participants needed
  • sponsor
    Jazz Pharmaceuticals
Updated on 22 December 2021


The purpose of study JZP110-405 is to determine whether solriamfetol is effective at improving cognitive function in participants with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA).

Condition Excessive Daytime Somnolence, Obstructive Sleep Apnea
Treatment Placebo, Solriamfetol
Clinical Study IdentifierNCT04789174
SponsorJazz Pharmaceuticals
Last Modified on22 December 2021


Yes No Not Sure

Inclusion Criteria

Male or female between 18 (or the legal age of consent in the jurisdiction in which the study takes place) and 65 years of age, inclusive
Diagnosis of OSA according to International Classification of Sleep Disorders, Third Edition criteria
Participant report (with clinician concurrence) of at least 1 of the following primary OSA therapy criteria
Consistent number of hours of primary PAP therapy use (with downloadable history) for OSA on at least 5 nights/week for at least 1 month prior to Baseline (with or without prior OSA surgical intervention), OR
No current use of PAP therapy for at least 1 month prior to Baseline but a history of at least 1 month of attempting to use PAP as the primary OSA therapy with at least 1 documented adjustment that was made in an attempt to optimize the therapy (with or without prior OSA surgical intervention), OR
History of a surgical intervention intended to treat OSA symptoms (with or without current PAP use as primary OSA therapy)
Usual nightly total sleep time of ≥ 6 hours
Body mass index from 18.5 to < 40 kg/m2
Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 14 days after the last dose of study
• Refrain from donating sperm
PLUS, either
Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR
Must agree to use contraception/barrier 7. A female participant is eligible to participate if she is not pregnant or
breastfeeding, and 1 of the following conditions applies
Is a woman of nonchildbearing potential (WONCBP) OR
Is a WOCBP and using a contraceptive method that is highly effective 8. Capable of giving signed informed consent

Exclusion Criteria

Female participants who are pregnant, nursing, or lactating
Usual bedtime later than 1 AM (0100 hours)
Occupation requiring nighttime or variable shift work
Unable to understand or perform DSST test per investigator's judgement
Use a PAP machine with no adherence data downloadable ability
Diagnosis of another sleep disorder (other than OSA) including: circadian rhythm sleep disorders, narcolepsy, restless legs syndrome determined by participant sleep history
Presence of acutely unstable major depression or current major depressive episode as based on the judgement of the investigator
Participants with active clinically significant illness, including endocrine, neoplastic, gastrointestinal, hematological, hepatic, immunologic, metabolic, neurological, pulmonary, and/or renal disease, and/or surgical history which could interfere with the study efficacy, safety, conduct or the ability of the participant to complete the study based on the judgement of the investigator, or place the participant at risk during the trial or compromise the study objectives
History or presence of any other clinically relevant medical, behavioral, or psychiatric disorder other than OSA that is associated with an impact on cognitive function
History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria
History of bariatric surgery within the past year or a history of any gastric bypass procedure
Participants with movement or motor disorders such as Parkinson's disease, as they will not be able to complete the DSST
Presence of renal impairment or calculated creatinine clearance < 60 mL/minute
Clinically significant ECG abnormality in the opinion of the investigator
Presence of significant cardiovascular disease
Laboratory value(s) outside the laboratory reference range that is considered to be clinically significant by the investigator (clinical chemistry, hematology, and urinalysis). NOTE: Screening labs may be repeated once
Hypothyroidism or hyperthyroidism, unless stabilized by appropriate medication for at least 3 months prior to Screening (a normal thyroid-stimulating hormone is required prior to Randomization at Baseline)
Use of any over-the-counter (OTC) or prescription medications that could affect the evaluation of EDS within a time period prior to the Baseline visit corresponding to at least 5 half-lives of the drug(s) or planned use of such drug(s) at some point throughout the duration of the 5-week double-blind treatment period
Current or recent (within the past 2 years) diagnosis of a moderate or severe substance use disorder (excluding caffeine) according to DSM-5 criteria, or seeking treatment for a substance-related disorder. Nicotine use disorder is excluded only if it has an effect on sleep (ie, a participant who routinely awakens at night to smoke)
Excessive caffeine use
Urine drug screen positive for amphetamine, methamphetamine, tricyclic antidepressants, propoxyphene, benzodiazepines, barbiturates, cocaine, marijuana, morphine, ecstasy, oxycodone, buprenorphine, methadone, or phencyclidine at Screening or at any point throughout the duration of the study
History of regular heavy use of tetrahydrocannabinol (THC) is excluded. Sporadic recreational users of THC can complete a repeat urine drug screen during the Screening period. If this is negative, the participant may be allowed to enter the study pending agreement to completely refrain from the use of THC during the course of the study
Positive alcohol test at Screening
Participants who binge drink, defined as 5 or more drinks in a day for men or 4 or more drinks in a day for women at least once in past month
History of phenylketonuria or history of hypersensitivity to phenylalanine-derived products
Currently receiving MAO inhibitors or having had received MAO inhibitors for 14 days prior to the Baseline visit
Previous exposure to solriamfetol
Received an investigational drug in the past 30 days or 5 half-lives (whichever is longer) prior to the Baseline visit, or plans to use an investigational drug (other than the study drug) during the study
Is currently participating in another clinical study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note